Ideas
How better measurements become better decisions, and how diagnostics, precision medicine, early detection and prevention can change clinical care.
Questions
Places represented
Geographic perspectives within this idea territory.
A curated route into the central arguments, rather than a chronological dump.
published on Linkedin on 20 July 2025. Every week, my LinkedIn feed is filled with billion-dollar AI alliances, breakthrough biomarker announcements, and government blueprints for “future healthcare.” Locally and globally, the numbers are extraordinary: the global precision medicine market is set to reach USD 119 billion in 2025 and leap to USD 470 billion by…
Read →Published on linkedin on June 17th 1. Not enough evidence! When we first embarked on developing Hepatopredict, our idea was very clear: create a biomarker-based test that could reliably inform clinical decisions about liver transplantation in patients with hepatocellular carcinoma (HCC). In our minds, the pathway was straightforward: demonstrate a strong correlation with clinical outcomes,…
Read →At 35, Sarah suffered a heart attack that a €30 genetic test could have prevented. Her story isn’t unusual, it’s a mirror of how health systems worldwide confuse “standard care” with equity. Sarah, a 34-year-old teacher, had visited her GP complaining of fatigue and chest tightness during exercise. Her cholesterol was significantly elevated at 8.2…
Read →“70% of clinical decisions depend on diagnostics.” You’ve seen this statistic, but it hides an important detail: timing. The acuity gradient: Lab testing occurs in 98% of inpatient encounters, 56% in emergency departments, but only 29% in outpatient settings (Ngo et al., 2017): diagnostics concentrate where disease is most advanced. Prevention is neglected: Evidence-based guidelines…
Read →